Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

112
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
112
Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Defining disease stability in COPD: Evidence from Phase 3 clinical trials.

American journal of respiratory and critical care medicine·2026
Same author

Using Off-Treatment Sequential Multiple Imputation for Binary Outcomes to Address Intercurrent Events Handled by a Treatment Policy Strategy.

Pharmaceutical statistics·2026
Same author

Strategic risk assessment in oncology: Utilizing single-agent activity to boost combination therapy approvals.

Contemporary clinical trials communications·2026
Same author

Clinical utility of serial plasma cell-free DNA metagenomic next-generation sequencing assays.

Infection control and hospital epidemiology·2026
Same author

Correction: Risk Factors for Opioid Utilization in Patients with Intracerebral Hemorrhage.

Neurocritical care·2025
Same author

Multivariate Bayesian Dynamic Borrowing for Repeated Measures Data With Application to External Control Arms in Open-Label Extension Studies.

Biometrical journal. Biometrische Zeitschrift·2025
Same journal

Latent Class Log-Linear Models for Estimating Diagnostic Test Accuracy Without a Gold Standard: A Simulation Study.

Statistics in medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
查看所有相关文章

相关实验视频

Updated: May 28, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

使用胜利几率来改善瘤学中的承诺到第三阶段的决策.

Benjamin F Hartley1, Thomas Drury2, Brian Di Pace3

  • 1Veramed Ltd., Twickenham, UK.

Statistics in medicine
|February 14, 2025
PubMed
概括
此摘要是机器生成的。

一个新的赢得机会框架改善了承诺进行癌症临床试验的决策. 与现有方法相比,这种方法更好地预测整体生存结果.

关键词:
多状态模型的多状态模型.第二阶段临床试验.定量决策 量化决策 量化决策替代终点的替代终点.赢得统计数据的统计

更多相关视频

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

204
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

相关实验视频

Last Updated: May 28, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

204
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

科学领域:

  • 临床试验 临床试验
  • 在瘤学瘤学.
  • 生物统计学 生物统计学

背景情况:

  • 决定将瘤药物推进到临床试验的第三阶段是复杂的.
  • 了解注册终点 (例如整体存活率) 和代用终点 (例如无进展存活率,客观反应) 之间的关系至关重要,但往往有限.

研究的目的:

  • 提出一个新的决策框架,用于承诺进行第三阶段瘤学试验.
  • 引入和评估"三个终点胜利几率"作为改善决策的指标.

主要方法:

  • 开发了一个基于三个终点的胜利几率的决策框架.
  • 将胜利几率解释为整体生存的平均危险比率的相反值.
  • 使用多状态疾病模型模拟相关的患者级瘤学终点.
  • 用模拟研究和临床试验案例研究验证了该方法.

主要成果:

  • 赢得几率框架为瘤药物开发的决策提供了一个强大的方法.
  • 模拟研究证实了胜利赔率方法的性能.
  • 多状态模型成功生成了临床上现实的数据进行分析.

结论:

  • 与现有方法相比,赢得几率框架为瘤学中承诺到第三阶段的决策提供了一种优越的方法.
  • 该框架增强了基于早期临床试验终点的整体存活率的理解和预测.